Literature DB >> 8313512

Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases alpha and pi in human renal cell carcinoma and in kidney cancer-derived cell lines.

P Eickelmann1, T Ebert, U Warskulat, W A Schulz, H Sies.   

Abstract

NAD(P)H:quinone oxidoreductase (NQOR) and glutathione S-transferases (GST) are enzymes of interest in cell defence and drug resistance. Relative levels of NQOR mRNA in renal cell carcinomas were 28 +/- 24% (n = 21) of those in non-neoplastic tissue and the enzyme activity decreased from 41 +/- 39 to 18 +/- 27 mU/mg protein (n = 23). In three of the cases, there was no measurable NQOR enzyme activity at all, indicating a polymorphism in the population for this gene. Relative GST-alpha mRNA levels in the tumours were on average 6 +/- 6% (n = 22) of the control value, whereas for GST-pi mRNA smaller decreases as well as increases were found in the tumours as compared to control tissue, but, on average, the level remained unchanged. Overall GST activity measured with CDNB as a substrate was 152 +/- 157 mU/mg protein in tumour tissue and 342 +/- 177 mU/mg protein in non-neoplastic tissue (n = 23). In all kidney tumour-derived cell lines NQOR mRNA was strongly expressed and on a per protein basis NQOR activity was about 10-fold higher than in the kidney tumour samples. GST-pi but not GST-alpha mRNA was also present. Total GST enzyme activities in these cell lines were similar to those in kidney tumour samples. HepG2 cells exhibited expression of NQOR and GST-alpha; GST-pi was not detectable. NQOR activity in HepG2 was about four-fold higher than in kidney-derived cell lines. Thus, NQOR and GST-alpha are both down-regulated in renal carcinoma, but their expression diverges in carcinoma cell lines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8313512     DOI: 10.1093/carcin/15.2.219

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

Review 1.  Benzene, NQO1, and genetic susceptibility to cancer.

Authors:  M T Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

2.  r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step.

Authors:  Kevin W Hallgren; Wen Qian; Anna V Yakubenko; Kurt W Runge; Kathleen L Berkner
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

Review 3.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

4.  Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines.

Authors:  M O Grimm; B Jürgens; W A Schulz; K Decken; D Makri; B J Schmitz-Dräger
Journal:  Urol Res       Date:  1995

5.  A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity.

Authors:  D Ross; R D Traver; D Siegel; B L Kuehl; V Misra; A M Rauth
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

6.  The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma.

Authors:  Giuseppe De Palma; Fabio Sallustio; Claudia Curci; Vanessa Galleggiante; Monica Rutigliano; Grazia Serino; Pasquale Ditonno; Michele Battaglia; Francesco P Schena
Journal:  J Cancer       Date:  2016-09-27       Impact factor: 4.207

7.  Presence of a heterozygous substitution and its relationship to DT-diaphorase activity.

Authors:  B L Kuehl; J W Paterson; J W Peacock; M C Paterson; A M Rauth
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

8.  DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?

Authors:  E Smitskamp-Wilms; G Giaccone; H M Pinedo; B F van der Laan; G J Peters
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.